Invivyd’s Pemgarda Gets EUA for Covid
Federal Register notice: FDA is announcing the issuance of an emergency use authorization for Invivyd’s Pemgarda (pemivibart) for use as Covid-19 pre-exposure prophylaxis in certain adults and adolescents. Pemgarda is a recombinant monoclonal lgGh antibody that targets the Covid spike protein receptor binding domain, thereby inhibiting virus attachment to the the human ACE2 receptor on host cells. To view the notice, click here.